for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Infinity Pharmaceuticals Inc.

INFI.OQ

Latest Trade

1.19USD

Change

0.03(+2.59%)

Volume

25,262

Today's Range

1.16

 - 

1.19

52 Week Range

1.00

 - 

2.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.16
Open
1.16
Volume
25,262
3M AVG Volume
1.61
Today's High
1.19
Today's Low
1.16
52 Week High
2.92
52 Week Low
1.00
Shares Out (MIL)
57.03
Market Cap (MIL)
66.15
Forward P/E
-1.61
Dividend (Yield %)
--

Next Event

Q3 2019 Infinity Pharmaceuticals Inc Earnings Release

Latest Developments

More

Infinity Pharmaceuticals Expects Net Loss For 2019 To Range From $40 Mln To $50 Mln

Infinity Pharmaceuticals Q1 Loss Per Share $0.24

Infinity Pharmaceuticals Inc Files For Mixed Shelf Of Upto $100 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Infinity Pharmaceuticals Inc.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Industry

Biotechnology & Drugs

Contact Info

1100 Massachusetts Ave Ste 4

+1.617.4531000

http://www.infi.com

Executive Leadership

Adelene Q. Perkins

Chairman of the Board, Chief Executive Officer

Lawrence E. Bloch

President, Chief Financial Officer, Chief Accounting Officer, Treasurer

Jeffery L. Kutok

Senior Vice President, Chief Scientific Officer

Seth A. Tasker

Vice President, General Counsel, Secretary

Samuel Agresta

Chief Medical Officer

Key Stats

2.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.610

2017

-0.830

2018

-0.200

2019(E)

-0.719
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.70
Price To Book (MRQ)
2.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-36.09
Return on Equity (TTM)
-31.91

Latest News

BRIEF-Infinity To Initiate Study Evaluating IPI-549 In Front-Line Triple Negative Breast Cancer And Renal Cell Cancer

* INFINITY TO INITIATE MARIO-3, A PHASE 2 MULTI-ARM STUDY EVALUATING IPI-549 IN FRONT-LINE TRIPLE NEGATIVE BREAST CANCER AND RENAL CELL CANCER

BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

* Q1 EARNINGS PER SHARE VIEW $-0.18 -- THOMSON REUTERS I/B/E/S

BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18

* INFINITY PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, DILUTED LOSS PER COMMON SHARE WAS $0.18 - SEC FILING

BRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing

* INFINITY PHARMACEUTICALS INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 1.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text: (https://bit.ly/2HF2NcI) Further company coverage:

BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10

* BVF PARTNERS LP REPORTS 21.7 PCT STAKE IN INFINITY PHARMACEUTICALS INC AS OF APRIL 10 - SEC FILING

BRIEF-Infinity Pharma Qtrly Diluted Loss Per Common Share $0.14​

* INFINITY PHARMACEUTICALS PROVIDES COMPANY UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Infinity Expects Net Loss For 2018 To Range From $40 Mln To $50 Mln​

* INFINITY PHARMACEUTICALS INC - INFINITY EXPECTS NET LOSS FOR 2018 TO RANGE FROM $40 MILLION TO $50 MILLION

BRIEF-Infinity Q3 loss per share $0.14

* Infinity provides company update and reports third quarter 2017 financial results

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration

* Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration evaluating ipi-549 in combination with Opdivo (nivolumab)

BRIEF-Infinity Q2 loss per share $0.34

* Infinity provides company update and reports second quarter 2017 financial results

BRIEF-Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology

* Infinity amends PI3K-Delta,Gamma Agreement with Takeda Oncology

BRIEF-Infinity reports Q1 loss per share $0.21

* Infinity provides company update and reports first quarter 2017 financial results

BRIEF-Infinity expects net loss for 2017 to range from $40 mln-$50 mln

* Infinity provides company update and reports fourth quarter 2016 financial results

BRIEF-Infinity expects net loss for 2017 in the range of $40 mln to $50 mln

* Infinity Pharmaceuticals Inc - expects to end 2017 with a year-end cash and investments balance ranging from $40 million to $50 million

BRIEF-Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors

* Bristol-Myers Squibb and infinity pharmaceuticals announce clinical collaboration to evaluate Opdivo (nivolumab) in combination with IPI-549 in advanced solid tumors

BRIEF-Verastem licenses duvelisib from infinity pharmaceuticals

* Verastem is obligated to pay to infinity up to $28 million in milestones

BRIEF-Verastem licenses Duvelisib from Infinity Pharmaceuticals

* Verastem inc says under terms of license agreement, Verastem is obligated to pay to Infinity up to $28 million in milestones Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up